The Philip Salem Chair in Cancer Research, created in 2010 to honor the pioneering physician's contributions to cancer medicine, has supported a number of studies over the past 12 months and we hope it will continue to pave the way for future physicians to research and discover new treatments.


  • A study of the use of nano materials (extremely tiny molecules or structures) to diagnose and treat cancer. Most nano materials are difficult and expensive to produce in useful quantities. This project by Stuart Corr, BEng,  MEng, PhD, is a collaborative study that takes advantage of the equipment, expertise and talents of a team at Baylor College of Medicine who are experts in electromagnetic fields.  Dr. Corr is an assistant professor and director of technology development at Baylor College of Medicine. This study will radically alter and improve the ability to produce carbon nanotubes in amounts sufficient for cancer and other biomedical uses – ultimately improving outcomes for patients.
  • A study by Christy Chai, MD, into the feasibility surgical telementoring for oncology and research by David Moore, PhD, into the impact of the use of meclizine on clinical outcomes.
  • Work by Norman Sussman, associate professor in the Division of Abdominal Transplantation at Baylor College of Medicine and medical director of Project ECHO at Baylor St. Luke’s Medical Center, along with Dr. Corr and Matthew J. Ware, PhD, MD, to develop a system with that would essentially function as an artificial liver for patients with liver failure or liver cancer. The development of this liver support system could ultimately supply the biochemical function of the liver and allow patients to be stabilized before transplantation or, in the case of acute liver failure, allow their own liver sufficient time to recover – much like dialysis does for kidneys.
  • A study by Hop Tran Cao, MD, of the use of new technology that can detect even microscopic nests of cancer cells left behind after surgical removal of breast cancer. This technology could prevent the need for a second operation to remove cancer cells that have been left behind and reduce the chance of cancer returning in the same breast. If the technology proves successful, it could be adapted for use in other types of cancer surgeries to assure that all malignant tissues and tumor cells have been removed.